Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.
INTRODUCTION — Systemic lupus erythematosus (SLE) predominantly affects women of childbearing age. Fertility in SLE patients does not appear to be altered by disease itself; however, a decrease in ovarian reserve can occur in women exposed to cyclophosphamide.
Pregnancy in women with SLE carries a higher maternal and fetal risk compared with pregnancy in healthy women. The prognosis for both mother and child is best when SLE has been quiescent for at least six months prior to the pregnancy. Disease flares during SLE pregnancy pose challenges with respect to distinguishing physiologic changes related to pregnancy from disease-related manifestations. Thus, a multidisciplinary approach with close medical, obstetric, and neonatal monitoring is necessary to optimize both maternal and fetal outcomes.
This topic review will discuss the major risks associated with pregnancy in SLE patients, as well as management recommendations. Issues related to menstrual function, menopause, estrogen replacement therapy, and the use of oral contraceptives in women with systemic lupus erythematosus are presented separately (see "Menstrual function, menopause, and hormone replacement therapy in women with systemic lupus erythematosus" and "Approach to contraception in women with systemic lupus erythematosus"). Issues related to pregnancy in patients with impaired renal function or with antiphospholipid syndrome (APS) are also presented elsewhere. (See "Pregnancy in women with underlying renal disease" and "Management of antiphospholipid syndrome in pregnant and postpartum women" and "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis".)
PREGNANCY PLANNING — Ideally, disease should be quiescent for six months prior to systemic lupus erythematosus (SLE) patients attempting conception. Active SLE at the time of conception is a strong predictor of adverse maternal and obstetrical outcomes [1-3]. In spite of this risk, the majority of such pregnancies still result in live births. The following studies are illustrative:
●The largest observational study, including 385 pregnant lupus patients with inactive or mild or moderate disease at conception, found 81 percent of subjects had uncomplicated pregnancies . After controlling for baseline risk factors such as lupus anticoagulant, treatment for hypertension, thrombocytopenia, disease flare, or moderate disease activity at baseline, non-Hispanic white patients had an 8 percent rate of adverse pregnancy outcomes. However, the study population was limited as it excluded women with high disease activity, active lupus nephritis, uncontrolled hypertension, and diabetes.
●A study of 267 pregnancies in a cohort of lupus patients found that women with high disease activity compared with low disease activity in the first and second trimesters showed a threefold increase in pregnancy loss (miscarriages and perinatal mortality) . However, overall there was no statistically significant difference in the number of live births between the women with high disease activity compared with low disease activity (77 percent versus 88 percent, respectively).
Our approach to pregnancy planning and management in SLE is generally consistent with recommendations developed by the European League Against Rheumatism (EULAR) .
Preconception evaluation — A preconception assessment is essential in women with SLE to determine whether pregnancy may pose an unacceptably high maternal or fetal risk, to initiate interventions to optimize disease activity, and to adjust medications to those that are least harmful to the fetus.
Women should be advised that discontinuation of medications used to control disease activity increases the risk of lupus flare and pregnancy complications. Ideally, women considering conception should be maintained on medications that are compatible with pregnancy and should continue these medications in pregnancy. Clinical features specific to pregnancy in the setting of SLE are discussed below. A more general discussion on preconception care and risk assessment in all women is presented separately. (See "The preconception office visit".)
Risk assessment — The preconception evaluation in women with SLE should include an assessment of disease activity and major organ involvement, as well as hypercoagulability or concurrent medical disorders that may impact pregnancy. Previous obstetric outcomes should be reviewed, with particular attention paid to history of small for gestational age fetus, preeclampsia, stillbirth, miscarriage, and preterm birth. An approach to the assessment of disease activity and severity of SLE is discussed separately. (See "Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Assessment of disease activity and severity'.)
Patients with evidence of active SLE, especially lupus nephritis, should be advised to defer pregnancy until the disease is well controlled for at least six months. For those with renal insufficiency, counseling should include an assessment of the risk of temporary or permanent decline in renal function. (See "Pregnancy in women with underlying renal disease".)
Increased severity of maternal disease generally correlates with higher maternal and fetal risk in pregnancy. Thus, recent stroke, cardiac involvement, pulmonary hypertension, severe interstitial lung disease, and advanced renal insufficiency can be dangerous to both mother and fetus. Women with these or other worrisome medical conditions should be counseled carefully by a Maternal Fetal Medicine specialist as to their individual risk profile, with clear discussion of the morbidity and mortality risks to both mother and fetus associated with pregnancy. Alternatives such as surrogacy and adoption should be presented. Should they elect to pursue pregnancy, they should be followed in a multidisciplinary fashion in a high-risk center [6,7].
Specific maternal antibody status such as antiphospholipid antibodies (aPLs) and antibodies to Ro/La should be assessed. aPLs may increase obstetric risks such as recurrent pregnancy loss, stillbirths, and preeclampsia while antibodies to Ro/La predispose to neonatal lupus (NL) . (See "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis" and "Management of antiphospholipid syndrome in pregnant and postpartum women".)
Specific laboratory testing — In addition to routine preconception labs (see "The preconception office visit", section on 'Laboratory assessment'), the following should be reviewed during the preconception evaluation (see "Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Laboratory evaluation'):
●aPLs: lupus anticoagulant (LA), immunoglobulin G (IgG) and IgM anticardiolipin (aCL) antibodies, and IgG and IgM anti-beta2-glycoprotein (GP) I antibodies
●Anti-Ro/SSA and anti-La/SSB antibodies
●Renal function (creatinine, urinalysis with urine sediment, spot urine protein/creatinine ratio)
●Complete blood count (CBC)
●Liver function tests
●Anti-double-stranded deoxyribonucleic acid (dsDNA) antibodies
●Complement (CH50, or C3 and C4)
Medications — Medications must be reviewed and adjusted prior to conception with the goal of maintaining disease control with medications with the best safety profile during pregnancy. Although many medications used to treat SLE are potentially harmful or contraindicated during pregnancy, there are some safer options. Information regarding the use of immunosuppressive agents in pregnant patients with SLE can be found below, and in a separate topic (see "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation"). The most commonly used medications used to treat patients with SLE are reviewed briefly below.
Selective use allowed during pregnancy — The following drugs have a reasonable safety profile during pregnancy, but certain limitations apply to their use. Nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, azathioprine, and some antihypertensive medications are included in this category. They each have a small risk of causing fetal harm, but their use may be acceptable if needed to control manifestations of SLE during pregnancy.
●Nonsteroidal antiinflammatory drugs – NSAID use is not strongly associated with congenital anomalies. However, the use of NSAIDs during a conception cycle may impede ovulation or implantation and is best avoided during a conception cycle. There is conflicting evidence as to whether exposure to NSAIDs during the first trimester increases the risk of spontaneous abortion. The use of NSAIDs in the third trimester may cause premature closure of the ductus arteriosus as well as other complications, and should be avoided during that time. Low-dose aspirin can be safely used in pregnancy and is often indicated to reduce the risk of preeclampsia . (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'NSAIDs and moderate to high-dose aspirin'.)
●Hydroxychloroquine – Hydroxychloroquine (HCQ) should be continued during pregnancy in all patients with SLE, unless otherwise contraindicated. Several studies have demonstrated fewer disease flares and better outcomes in patients continuing HCQ during pregnancy, with no increase in adverse events or congenital malformations [9-15]. Additionally, some data suggest a decrease in occurrence of congenital heart block in at-risk fetuses of mothers with anti-Ro/SSA and anti-LA/SSB antibodies exposed to HCQ . (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Hydroxychloroquine'.)
●Glucocorticoids – Glucocorticoids are used for a wide range of maternal diseases in pregnancy. We suggest control of disease with the lowest possible dose of prednisone, ideally less than 10 mg/day. While there have been some reports of glucocorticoid use during the first trimester that has been associated with cleft lip, with and without cleft palate, subsequent studies have failed to consistently demonstrate an increased risk of this malformation. Maternal and fetal adverse effects of glucocorticoids are discussed in detail separately. (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Glucocorticoids'.)
●Azathioprine – Azathioprine is considered relatively safe during pregnancy, but doses should not exceed 2 mg/kg/day. (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Azathioprine and 6-MP'.)
●Cyclosporine – Limited observations suggest that children exposed in utero to cyclosporine have normal renal function and blood pressure. The manufacturer suggests that use in pregnancy should be limited to when maternal benefit outweighs fetal risk. (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Cyclosporine'.)
●Tacrolimus – A causal relationship between tacrolimus use and birth defects has not been found, though the number of fetuses exposed in utero has been small. An small case series of nine pregnant lupus patients reported successful disease maintenance or control of lupus nephritis flares with tacrolimus  (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Tacrolimus'.)
●Antihypertensive medications – Methyldopa, labetalol, nifedipine, and hydralazine are the most commonly used antihypertensives in pregnancy. By comparison, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers are contraindicated during pregnancy. Diuretics should be used with caution. Nitroprusside is the agent of last resort for urgent control of refractory severe hypertension; its use should be limited to a short period of time in an emergency situation. (See "Management of hypertension in pregnant and postpartum women" and "Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy".)
Selective use with caution in pregnancy
●Biologic medications – Data regarding the use of biologic medications such as the B-cell depleting antibody, rituximab, or the BAFF inhibitor, belimumab, during pregnancy are limited. Case reports suggest that B-cell lymphocytopenia lasting up to six months in rituximab-exposed infants may occur. Thus, we discourage the use of these agents during pregnancy. (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Rituximab'.)
Contraindicated in pregnancy
●Cyclophosphamide – Cyclophosphamide is associated with congenital (or fetal) malformations and should be avoided during the first 10 weeks of gestation, when the fetus is most susceptible to teratogens (figure 1). However, this medication has been used in late pregnancy in life-threatening clinical situations. (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Cyclophosphamide'.)
●Mycophenolate mofetil – Congenital anomalies have been reported in infants exposed to mycophenolate mofetil during pregnancy. This medication should be avoided during pregnancy. (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Mycophenolate mofetil'.)
Azathioprine or tacrolimus can be substituted for mycophenolate prior to and during pregnancy, or, alternatively, glucocorticoids may be used at the lowest dose that controls disease activity. (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Azathioprine and 6-MP'.)
●Methotrexate – Methotrexate is teratogenic and should not be used during pregnancy. (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation", section on 'Methotrexate'.)
●Leflunomide – Pregnancy should be deferred for two years after discontinuation of leflunomide (or a washout procedure should be employed), since this drug can remain detectable in the serum for up to two years. (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation".)
Ideally conception should only be attempted in a state of disease remission or stable disease on medications compatible with pregnancy. However, if pregnancy occurs during a period of disease activity, medications will need to be adjusted for fetal and maternal safety.
SPECIFIC CONSIDERATIONS DURING PREGNANCY
Exacerbation of SLE — Although it is generally accepted that pregnancy and the postpartum period are associated with a higher rate of systemic lupus erythematosus (SLE) disease flares, widely variable rates have been reported ranging from 25 to 60 percent [3,7,18,19]. Some of this variation may be attributed to the heterogeneous study designs, diverse patient and control groups, and different definitions of flares used in the studies.
The following factors are associated with an increased risk of SLE flare during pregnancy [1,9,20-22]:
●Active disease during the six months prior to conception
●A history of lupus nephritis
●Discontinuation of hydroxychloroquine (HCQ)
Impact of lupus on pregnancy — Pregnancy in the setting of SLE is associated with a higher risk of complications compared with healthy women. The largest study to evaluate maternal and pregnancy complications associated with SLE included 13,555 pregnancies . Women with SLE also had a two- to fourfold increased rate of obstetric complications including preterm labor, unplanned cesarean delivery, fetal growth restriction, preeclampsia, and eclampsia. Patients with SLE also had a significantly higher risk of thrombosis, infection, thrombocytopenia, and transfusion. This study also reported that maternal mortality was 20-fold higher among women with SLE; however, mortality amongst similar-aged SLE patients who were not pregnant was even higher. Another study found that increased rates of hypertension during pregnancy, preterm delivery, unplanned cesarean delivery, postpartum hemorrhage, and maternal venous thromboembolism were all more frequent in women with SLE compared with pregnancies of women without SLE .
Several predictors of adverse pregnancy outcomes among women with SLE have been identified and include active disease, use of antihypertensives, prior lupus nephritis, the presence of antiphospholipid antibodies (aPLs), and thrombocytopenia [4,25]. Moreover, primigravidas are at higher risk for pregnancy complications .
Preeclampsia — Preeclampsia is one of the most frequent complications of pregnancy in SLE, occurring in 16 to 30 percent of women with SLE, compared with 4.6 percent of pregnancies in the general obstetric population [3,26-28]. Risk factors for preeclampsia in women with SLE are the same as those in healthy women and are discussed separately (see "Preeclampsia: Clinical features and diagnosis", section on 'Risk factors'). Additional risk factors for preeclampsia that are specific to SLE patients include an active or prior history of lupus nephritis, declining complement levels, and thrombocytopenia. The data on whether aPLs predispose to preeclampsia is unclear, although some studies suggest an association [26,29].
Preterm birth — Preterm birth is the most common obstetric complication in women with SLE. Rates of preterm birth from 15 to 50 percent are reported, with increased incidence in women with lupus nephritis or high disease activity. This compares with 12 percent of pregnancies in the general US obstetric population [1,21,26]. The presence of lupus nephritis and active disease are the strongest predictors for early delivery [18,27,30]. The rates of preterm birth are likely better among women without such risk factors . In addition to disease activity, other factors contributing to higher rates of preterm births include superimposed preeclampsia, intrauterine growth restriction, and likely higher rates of abruption, fetal stress, and exposure to glucocorticoids.
Fetal complications — Fetal complications during pregnancy in patients with SLE include fetal loss, growth restriction, neonatal lupus (NL) syndromes, and complications of prematurity.
●Fetal loss – Historically, significantly elevated rates of both early and late pregnancy loss have been seen in women with SLE. Most contemporary studies group all losses from the embryonic stage to stillbirth under the term “fetal loss,” making it challenging to interpret the risk of early miscarriage versus later fetal death.
The effect of SLE on embryonic losses is controversial, with a possible slight increase in risk. Women with SLE are at increased risk of fetal death beyond 10 weeks, particularly in the presence of active SLE, lupus nephritis, and antiphospholipid syndrome (APS). Overall, fetal loss rates amongst SLE patients have been declining over the last decades, with increased rates of livebirths [1,30,31]. A large observational cohort of patients with inactive lupus or mild to moderate disease activity at conception found that 5 percent of pregnancies ended in fetal or neonatal death .
●Fetal growth restriction – About 10 to 30 percent of pregnancies in women with SLE are complicated by fetal growth restriction and small-for-gestational-age babies compared with about 10 percent of pregnancies in the general obstetric population [18,21,32]. As with the other complications, the risk is higher in the presence of active disease, hypertension, and lupus nephritis. Lower birth weight at every gestational age is also more prevalent in women with SLE .
●Neonatal lupus – NL is a passively transferred autoimmune disease that occurs in some babies born to mothers with anti-Ro/SSA or anti-LA/SSB antibodies, who may or may not carry the diagnosis of SLE or Sjögren’s. The major manifestations of NL are either cutaneous or cardiac, but other manifestations of NL include hematologic and hepatic abnormalities.
The most serious complication in the neonate is congenital complete heart block, which occurs in approximately 2 percent of children born to primigravid women with anti-Ro/SSA antibodies . The risk of complete heart block increases to approximately 16 to 18 percent for subsequent pregnancies, or 10 to 15 percent when a previous infant had cutaneous NL [34-36]. Data suggest that congenital heart block may occur more frequently in the setting of anti-Ro52, as opposed to anti-Ro60 or anti-La antibodies; however, at this time, neonatal surveillance should not be altered by antibody type, and Ro antibody differentiation is not routinely performed to guide obstetric care . The pathogenesis, clinical manifestations, screening, prevention, and treatment of NL are discussed separately. (See "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis" and "Congenital third degree (complete) atrioventricular block".)
SLE does not appear to confer risks for other identifiable congenital abnormalities [38,39]. Some studies have found that learning disabilities may be more frequent in children, particularly sons, of SLE mothers, but more studies are needed to confirm this [40,41].
Lupus nephritis — Women with active lupus nephritis should be encouraged to delay pregnancy until the disease is inactive for at least six months to optimize maternal outcomes. As discussed above, a previous history of lupus nephritis or active lupus nephritis during pregnancy is associated with higher rates of maternal and fetal complications. The following examples are illustrative:
●An observational study with 193 pregnancies of 104 women with SLE, among which 81 occurred in the presence of active renal disease, found that low birth weight was observed more frequently in pregnancies with renal disease . The presence of active renal disease during pregnancy was also associated with an increased frequency of pregnancy-induced hypertension and lupus flares.
●Another retrospective study of 95 pregnancies among women with SLE found that a previous history of lupus nephritis was a predictor for adverse maternal outcomes . Pregnancies of women with previous nephritis were associated with a higher risk of maternal complications (88 percent versus 43 percent, respectively) and a higher rate of flares (54 percent versus 25 percent, respectively), most of which were renal flares. However, most renal flares in this cohort were not severe, responded to high doses of prednisone, and did not lead to pregnancy loss.
●A retrospective study of 90 pregnancies among 58 lupus patients found significantly lower rates of preeclampsia, preterm birth, and pregnancy loss among women with lupus nephritis in remission compared with women with active lupus nephritis (35, 30, and 25 percent versus 57, 52, and 35 percent, respectively) .
Thus, these women require careful monitoring during pregnancy, and may require medication to control their disease. A detailed discussion of pregnancy in women with underlying renal disease is presented separately (see "Pregnancy in women with underlying renal disease"), and the approach to therapy of a flare of lupus during pregnancy is discussed below. (See 'Management during pregnancy' below.)
Women with SLE who have received renal transplants have pregnancy outcomes that are similar to those of other transplant recipients . Management of pregnancy following renal transplantation is discussed separately. (See "Pregnancy in women with underlying renal disease", section on 'Pregnancy in the renal transplant recipient'.)
Presence of antiphospholipid antibodies — aPLs are present in about a quarter to a half of patients with SLE; however, few patients develop thrombotic or obstetric complications related to APS.
Pregnant women with SLE who have an obstetric history suggestive of APS (fetal death after 10 weeks or three or more consecutive miscarriages, or premature birth <34 weeks due to preeclampsia or placental insufficiency) or unexplained venous or arterial thrombotic event, should be tested for the presence of aPLs (ie, lupus anticoagulant [LA], immunoglobulin G [IgG] and IgM anticardiolipin [aCL] antibodies; and IgG and IgM anti-beta2-glycoprotein [GP] I). The clinical manifestations, diagnosis, and management of women with aPL who are contemplating pregnancy or who are pregnant are discussed in more detail separately. (See "Management of antiphospholipid syndrome in pregnant and postpartum women" and "Diagnosis of antiphospholipid syndrome".)
It is unclear whether women with aPLs without an APS diagnosis are at increased risk of pregnancy loss . Issues associated with the presence of these autoantibodies in pregnant women and the management of such patients is discussed separately. (See "Management of antiphospholipid syndrome in pregnant and postpartum women", section on 'aPL alone'.)
Presence of anti-Ro and anti-La antibodies — As mentioned above, a fetus exposed to anti-Ro/SSA and/or anti-La/SSB antibodies is at an increased risk of developing congenital complete heart block or NL (see 'Fetal complications' above). In most cases, congenital heart block develops between 18 and 24 weeks of gestation. Thus, in some centers, women who have antibodies to Ro/SSA and/or La/SSB undergo increased fetal surveillance for heart block, with differing surveillance protocols at different sites. While there is no therapeutic intervention proven to prevent progression, early detection allows for increased monitoring. HCQ use during pregnancy is associated with reduced rates of congenital heart block [44,45] (see "Neonatal lupus: Management and outcomes", section on 'Prevention of NL in subsequent pregnancies'). The monitoring and management of congenital heart block associated with NL is discussed in detail separately. (See "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Heart block' and "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Fetal surveillance for heart block' and "Neonatal lupus: Management and outcomes", section on 'In utero management'.)
Women with anti-Ro/SSA and anti-La/SSB may have detectable amounts of these antibodies in breast milk, but there is no evidence that NL results from breast feeding .
MANAGEMENT DURING PREGNANCY — Management of pregnant women with systemic lupus erythematosus (SLE) should involve close collaboration between a rheumatologist and an obstetrician experienced in caring for high-risk mothers. An approach to monitoring pregnant women with SLE as well as treating active SLE during pregnancy is presented below.
Monitoring SLE activity — Women should be assessed by a rheumatologist for disease activity at least once each trimester, and more frequently if they have active SLE. The schedule for monitoring includes:
Initial evaluation — At the first visit after (or at which) pregnancy is confirmed, the following investigations are recommended :
●Physical examination, including blood pressure
●Renal function (creatinine, urinalysis, spot urine protein/creatinine ratio)
●Complete blood count (CBC)
●Liver function tests
●Anti-Ro/SSA and anti-La/SSB antibodies
●Lupus anticoagulant (LA) and anticardiolipin antibody (aCL) assays
●Anti-double stranded DNA (dsDNA) antibodies
●Complement (CH50, or C3 and C4)
●Serum uric acid
Some physiological changes of pregnancy may overlap with features of active SLE, making differentiation difficult. As an example, laboratory findings that may be observed during a normal pregnancy include mild anemia, mild thrombocytopenia, elevated erythrocyte sedimentation rate (ESR), and proteinuria. Protein excretion increases in the course of normal pregnancy, but should remain below 300 mg/24 hours. A baseline 24-hour urine collection can be helpful in distinguishing lupus flare from preeclampsia and normal changes later in pregnancy (see 'Preeclampsia versus lupus nephritis' below). Also, during normal pregnancy, complement levels may rise by 10 to 50 percent, and may appear to remain normal despite active SLE. Thus, the trend of complement levels is generally more informative than the actual value.
Thus, laboratory testing must be interpreted in the clinical context and women who show evidence of increased serologic activity but who remain asymptomatic should be monitored more closely. We do not initiate therapy for serologic findings alone.
Laboratory testing — In addition to a physical examination with blood pressure testing, the following laboratory tests are recommended at regular intervals during pregnancy:
●Urinalysis with examination of urinary sediment
●Spot urine protein/creatinine ratio or 24-hour urine collection
●Complement (CH50, or C3 and C4)
Ordering additional laboratory tests such as liver function tests and serum uric acid should be guided by the clinical presentation. The frequency of laboratory testing is individualized and varies with disease activity. Patients with stable disease should ideally undergo laboratory testing each trimester, but those with active lupus will require more frequent testing.
Postpartum laboratory testing — Some women will experience exacerbations of SLE in the postpartum period. Those who have had active disease at conception and those with significant end-organ damage are at greater risk of disease flares in the postpartum period compared with women with inactive disease . Thus, periodic assessment of disease activity is warranted postpartum. The following laboratory tests are recommended at one month following an uncomplicated delivery :
●Urinalysis, urine protein/urine creatinine ratio
●Renal function if the urinalysis is abnormal
●Complement (CH50, or C3 and C4)
Treatment of postpartum women with active SLE is the same as that of nonpregnant women. Many medications are not compatible with breastfeeding; thus, breastfeeding women will require thoughtful discussions with their clinicians as to the risks and benefits of various treatment approaches. Medication safety in pregnancy differs in many instances from medication safety in lactation. (See 'Breastfeeding' below.)
Maternal-fetal monitoring — The optimal monitoring schedule to ensure maternal and fetal health during pregnancy is not known. Women with risk factors or poor prognostic indicators may require more frequent monitoring. In addition to routine prenatal care, fetal monitoring for women with SLE includes:
●First-trimester ultrasound evaluation to establish the estimated date of delivery. A fetal anatomic survey is performed at approximately 18 weeks of gestation.
●Ultrasound evaluation for fetal growth and placental insufficiency in the third trimester. Frequency of surveillance for fetal growth will depend upon maternal and fetal wellbeing, but typically will be performed approximately every four weeks. More frequent monitoring, including umbilical artery velocimetry, is also recommended if growth restriction or placental insufficiency is suspected. (See "Fetal growth restriction: Evaluation and management", section on 'Pregnancy management'.)
●Fetal testing with nonstress tests and/or biophysical profile during the final four to six weeks of pregnancy is indicated in most women with lupus, with individual surveillance plans based on fetal and maternal assessment. (See "Overview of antepartum fetal surveillance".)
●In patients with positive anti-Ro/SSA and/or anti-La/SSB antibodies, increased surveillance for congenital heart block is recommended. (See "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Fetal surveillance for heart block' and 'Presence of anti-Ro and anti-La antibodies' above.)
Preeclampsia — Women with SLE are at higher risk of preeclampsia than the general population. These patients require additional vigilance, as the presentation of hypertension, proteinuria, or end-organ dysfunction after 20 weeks of gestation is concerning for development of preeclampsia. Severe, early-onset growth restriction is similarly concerning for developing preeclampsia. While preeclampsia presenting later in pregnancy can often be managed expectantly, in pre-and peri-viable gestations, delivery is indicated to prevent catastrophic maternal complications. For this reason, early diagnosis is essential.
In women at elevated risk of preeclampsia, aspirin has been shown to reduce the risk of disease by 10 to 20 percent when initiated between 12 to 20 weeks gestation  (see "Preeclampsia: Prevention", section on 'Our approach to low-dose aspirin therapy'). Preeclampsia in women with antiphospholipid syndrome (APS) is discussed separately. (See "Management of antiphospholipid syndrome in pregnant and postpartum women".)
Preeclampsia versus lupus nephritis — Differentiating preeclampsia from lupus nephritis or a lupus flare can be challenging. Lupus nephritis flares during pregnancy can mimic preeclampsia, presenting with increasing proteinuria, hypertension, thrombocytopenia, and a deterioration in renal function. Active lupus nephritis and preeclampsia can also occur at the same time. Evidence of lupus activity in other organs can sometimes help distinguish SLE from preeclampsia.
Laboratory testing may be, but is not always, useful in distinguishing preeclampsia from nephritis or a lupus flare:
●Lupus nephritis is often associated with proteinuria and/or an active urine sediment (red and white cells and cellular casts), whereas only proteinuria is seen in preeclampsia.
●Flares of SLE are likely to be associated with low or decreasing complement levels and increased titers of anti-dsDNA antibodies; by comparison, complement levels are usually, but not always, normal or increased in preeclampsia [49,50].
●Thrombocytopenia, elevated serum levels of liver enzymes and an elevated or rising level of uric acid are more prominent in preeclampsia than lupus nephritis. However, thrombocytopenia may also be seen in association with antiphospholipid antibodies (aPLs), thrombotic thrombocytopenic purpura, and immune thrombocytopenia, each of which may complicate pregnancy in women with SLE.
The onset of these overlapping symptoms before 20 weeks of gestation is more consistent with lupus nephritis. Renal biopsy could help differentiate the two conditions, but the higher risk of complications during pregnancy limits the use in pregnancy. (See "Pregnancy in women with underlying renal disease", section on 'Kidney biopsy during pregnancy'.)
Treating active SLE — The treatment of active SLE during pregnancy is guided by the severity and degree of organ involvement, similar to patients in the non-pregnant state. Treatment should not be withheld due to pregnancy; however, some medications used to treat SLE may cross the placenta and cause fetal harm. Thus, the risks and benefits of treatment during pregnancy must be weighed against the risk of SLE activity having a deleterious effect on the mother and the fetus [51,52]. The most commonly used medications used to treat patients with SLE are reviewed above (see 'Medications' above). The use of immunosuppressive drugs during pregnancy is discussed in detail separately. (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation".)
A detailed discussion regarding the treatment of active lupus is presented separately. (See "Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Pharmacologic therapies'.)
Lupus nephritis in pregnancy requires special consideration because of its potential morbidity and possible confusion with preeclampsia. (See 'Lupus nephritis' above and 'Preeclampsia versus lupus nephritis' above.)
BREASTFEEDING — Breast feeding is encouraged for most women with systemic lupus erythematosus (SLE). The safety of medications in lactation sometimes differs, and their use should be discussed on an individual level and specific risks reviewed.
Hydroxychloroquine (HCQ), prednisone, cyclosporine, azathioprine, and tacrolimus are considered compatible with breast feeding. Methotrexate in low or intermittent doses is also considered compatible with breast feeding. Limited information on biologics or leflunomide is available. Cyclophosphamide is contraindicated in lactation. Premature or ill infants may be at increased risk of some medication exposures. Detailed information regarding compatibility of medications with lactation is provided by the United States National Library of Medicine (LactMed drug and lactation database) . A more detailed discussion on the use of immunosuppressive drugs during lactation can be found elsewhere. (See "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation".)
SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Systemic lupus erythematosus".)
INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
●Beyond the Basics topic (see "Patient education: Systemic lupus erythematosus and pregnancy (Beyond the Basics)")
SUMMARY AND RECOMMENDATIONS
●Ideally, all pregnancies in women with systemic lupus erythematosus (SLE) should be planned during periods of disease quiescence for at least six months prior to conception. Active SLE at the time of conception is a strong predictor of adverse maternal and obstetrical outcomes. In spite of this risk, the majority of such pregnancies still result in live births. (See 'Introduction' above and 'Pregnancy planning' above.)
●A preconception assessment is essential in women with SLE to determine whether pregnancy may pose an unacceptably high maternal or fetal risk, to initiate interventions to optimize disease activity, and to adjust medications to those that are least harmful to the fetus. (See 'Preconception evaluation' above.)
●Specific laboratory testing done as part of the preconception evaluation should include antiphospholipid antibodies (aPLs; lupus anticoagulant [LA], immunoglobulin G [IgG] and IgM anticardiolipin [aCL] antibodies, and IgG and IgM anti-beta2-glycoprotein [GP] I antibodies), anti-Ro/SSA and anti-La/SSB antibodies, anti-double-stranded deoxyribonucleic acid (dsDNA) antibodies, TSH, creatinine, urinalysis with urine sediment, spot urine protein/creatinine ratio, complete blood cell count (CBC), liver function tests, and complement levels (CH50, or C3 and C4) and a uric acid. (See 'Specific laboratory testing' above.)
●Medications must be reviewed and adjusted prior to conception with the goal of maintaining disease control with medications with the best safety profile during pregnancy. Although many medications used to treat SLE are potentially harmful or contraindicated during pregnancy, there are some safer options. (See 'Medications' above.)
●Other considerations during pregnancy in women with SLE include increased risk of disease flare, particularly among primigravidas and women with a history of lupus nephritis or active nephritis. Pregnancy among lupus patients is also associated with higher rates of complications such as preeclampsia, preterm birth, fetal loss, growth restriction, neonatal lupus (NL) syndromes, and complications of prematurity. (See 'Exacerbation of SLE' above and 'Impact of lupus on pregnancy' above and 'Fetal complications' above and 'Special considerations' above.)
●Management of pregnant women with SLE should involve close collaboration between a rheumatologist and an obstetrician experienced in caring for high risk mothers. Women should be assessed by a rheumatologist for disease activity at least once each trimester, and more frequently if they have active SLE. Periodic assessment of disease activity should also be continued through the postpartum period. (See 'Management during pregnancy' above and 'Monitoring SLE activity' above.)
●Women with risk factors or poor prognostic indicators may require more frequent maternal-fetal monitoring. In patients with positive anti-Ro/SSA and/or anti-La/SSB antibodies, increased surveillance for congenital heart block may be appropriate. (See 'Maternal-fetal monitoring' above.)
●Women with SLE and/or aPLs are at higher risk of preeclampsia than the general population, and treatment with a baby aspirin during pregnancy should be considered. These patients require additional vigilance, as the presentation of hypertension, proteinuria, or end-organ dysfunction after 20 weeks of gestation is concerning for development of preeclampsia. Lupus nephritis flares during pregnancy can mimic preeclampsia, and differentiating one from the other can be challenging. (See 'Preeclampsia' above and 'Preeclampsia versus lupus nephritis' above.)
●The treatment of active SLE during pregnancy is guided by the severity and degree of organ involvement, similar to patients in the non-pregnant state. Treatment should not be withheld due to pregnancy; however, some medications used to treat SLE may cross the placenta and cause fetal harm. Thus, the risks and benefits of treatment during pregnancy must be weighed against the risk of SLE activity having a deleterious effect on the mother and the fetus. (See 'Treating active SLE' above.)
ACKNOWLEDGMENT — The editorial staff at UpToDate would like to acknowledge Peter Schur, MD, who contributed to an earlier version of this topic review.
- Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005; 52:514.
- Yang H, Liu H, Xu D, et al. Pregnancy-related systemic lupus erythematosus: clinical features, outcome and risk factors of disease flares--a case control study. PLoS One 2014; 9:e104375.
- Kwok LW, Tam LS, Zhu T, et al. Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus 2011; 20:829.
- Buyon JP, Kim MY, Guerra MM, et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med 2015; 163:153.
- Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; 76:476.
- Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: ten questions and some answers. Lupus 2008; 17:416.
- Lateef A, Petri M. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol 2013; 27:435.
- Henderson JT, Whitlock EP, O'Conner E, et al. Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US) 2014.
- Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54:3640.
- Al-Herz A, Schulzer M, Esdaile JM. Survey of antimalarial use in lupus pregnancy and lactation. J Rheumatol 2002; 29:700.
- Parke AL, Rothfield NF. Antimalarial drugs in pregnancy--the North American experience. Lupus 1996; 5 Suppl 1:S67.
- Klinger G, Morad Y, Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001; 358:813.
- Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003; 48:3207.
- Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001; 10:401.
- Sperber K, Hom C, Chao CP, et al. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 2009; 7:9.
- Mekinian A, Lazzaroni MG, Kuzenko A, et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. Autoimmun Rev 2015; 14:498.
- Webster P, Wardle A, Bramham K, et al. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus 2014; 23:1192.
- Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5:2060.
- Petri M. Prospective study of systemic lupus erythematosus pregnancies. Lupus 2004; 13:688.
- Gladman DD, Tandon A, Ibañez D, Urowitz MB. The effect of lupus nephritis on pregnancy outcome and fetal and maternal complications. J Rheumatol 2010; 37:754.
- Saavedra MA, Cruz-Reyes C, Vera-Lastra O, et al. Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy. Clin Rheumatol 2012; 31:813.
- Saavedra MA, Sánchez A, Morales S, et al. Primigravida is associated with flare in women with systemic lupus erythematosus. Lupus 2015; 24:180.
- Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008; 199:127.e1.
- Yasmeen S, Wilkins EE, Field NT, et al. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med 2001; 10:91.
- Borella E, Lojacono A, Gatto M, et al. Predictors of maternal and fetal complications in SLE patients: a prospective study. Immunol Res 2014; 60:170.
- Chakravarty EF, Colón I, Langen ES, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol 2005; 192:1897.
- Bramham K, Hunt BJ, Bewley S, et al. Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. J Rheumatol 2011; 38:1906.
- Abalos E, Cuesta C, Grosso AL, et al. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol 2013; 170:1.
- Gibbins KJ, Ware Branch D. Pre-eclampsia as a manifestation of antiphospholipid syndrome: assessing the current status. Lupus 2014; 23:1229.
- Wagner SJ, Craici I, Reed D, et al. Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus 2009; 18:342.
- Carvalheiras G, Vita P, Marta S, et al. Pregnancy and systemic lupus erythematosus: review of clinical features and outcome of 51 pregnancies at a single institution. Clin Rev Allergy Immunol 2010; 38:302.
- Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am 2007; 33:237.
- Brucato A, Frassi M, Franceschini F, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44:1832.
- Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31:1658.
- Izmirly PM, Llanos C, Lee LA, et al. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum 2010; 62:1153.
- Llanos C, Izmirly PM, Katholi M, et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009; 60:3091.
- Ambrosi A, Wahren-Herlenius M. Congenital heart block: evidence for a pathogenic role of maternal autoantibodies. Arthritis Res Ther 2012; 14:208.
- Barnabe C, Faris PD, Quan H. Canadian pregnancy outcomes in rheumatoid arthritis and systemic lupus erythematosus. Int J Rheumatol 2011; 2011:345727.
- Nalli C, Iodice A, Andreoli L, et al. Children born to SLE and APS mothers. Lupus 2014; 23:1246.
- Ross G, Sammaritano L, Nass R, Lockshin M. Effects of mothers' autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med 2003; 157:397.
- Vinet É, Pineau CA, Clarke AE, et al. Neurodevelopmental disorders in children born to mothers with systemic lupus erythematosus. Lupus 2014; 23:1099.
- McGrory CH, McCloskey LJ, DeHoratius RJ, et al. Pregnancy outcomes in female renal recipients: a comparison of systemic lupus erythematosus with other diagnoses. Am J Transplant 2003; 3:35.
- Chighizola CB, Andreoli L, de Jesus GR, et al. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus 2015; 24:980.
- Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010; 69:1827.
- Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126:76.
- Askanase AD, Miranda-Carus ME, Tang X, et al. The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: implications in neonatal lupus. Arthritis Rheum 2002; 46:269.
- Lockshin MD, Sammaritano LR. Lupus pregnancy. Autoimmunity 2003; 36:33.
- Andrade RM, McGwin G Jr, Alarcón GS, et al. Predictors of post-partum damage accrual in systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (XXXVIII). Rheumatology (Oxford) 2006; 45:1380.
- Buyon JP, Cronstein BN, Morris M, et al. Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia. Am J Med 1986; 81:194.
- Buyon JP, Tamerius J, Ordorica S, et al. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum 1992; 35:55.
- Boumpas DT, Fessler BJ, Austin HA 3rd, et al. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995; 123:42.
- Lockshin MD, Harpel PC, Druzin ML, et al. Lupus pregnancy. II. Unusual pattern of hypocomplementemia and thrombocytopenia in the pregnant patient. Arthritis Rheum 1985; 28:58.
- Drugs and lactation database (LactMed) of the United States National Library of Medicine http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT (Accessed on March 15, 2012).